$
289.920
-2.47(-0.845%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
290.190
Open
290.190
VWAP
--
Vol
193.13K
Mkt Cap
78.11B
Low
286.250
Amount
--
EV/EBITDA(TTM)
8.11
Total Shares
284.07M
EV
99.68B
EV/OCF(TTM)
13.39
P/S(TTM)
0.32
The Cigna Group is a global health company. The Company has two growth platforms: Evernorth Health Services and Cigna Healthcare. Evernorth Health Services includes its Pharmacy Benefit Services and Specialty and Care Services operating segments, which provide independent and coordinated health solutions and capabilities to enable the healthcare system to work better and help people live richer, healthier lives. Cigna Healthcare includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical plan services and coordinated solutions to clients and customers. Its Other Operations include corporate-owned life insurance (COLI), the Company's run-off operations and other non-strategic businesses. Specialty and Care Services provides specialty drugs for the treatment of complex and rare diseases, specialty distribution of pharmaceuticals and medical supplies, and clinical programs to help its clients.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
65.76B
+0.12%
7.910
+19.12%
64.22B
+0.83%
7.893
+5.1%
62.61B
+3.53%
7.156
+6.49%
Estimates Revision
The market is revising Upward the revenue expectations for The Cigna Group (CI) for FY2025, with the revenue forecasts being adjusted by 1.93% over the past three months. During the same period, the stock price has changed by -14.02%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.93%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+0.26%
In Past 3 Month
Stock Price
Go Down
down Image
-14.02%
In Past 3 Month
17 Analyst Rating
up Image
31.44% Upside
Wall Street analysts forecast CI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CI is 381.06 USD with a low forecast of 341.00 USD and a high forecast of 407.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Buy
4 Hold
0 Sell
Strong Buy
up Image
31.44% Upside
Current: 289.920
sliders
Low
341.00
Averages
381.06
High
407.00
Barclays
Overweight
maintain
$382 -> $385
2025-06-02
Reason
Guggenheim
Guggenheim
Buy
maintain
$928 -> $936
2025-05-23
Reason
Citi
Sell
maintain
$30
2025-05-22
Reason
Truist
David MacDonald
Buy
maintain
$385 -> $405
2025-05-12
Reason
Truist analyst David MacDonald raised the firm's price target on Cigna to $405 from $385 and keeps a Buy rating on the shares as part of a broader research note on Health Care Services. The firm is updating its models to reflect Q1 results and updated guidance on select names, the analyst tells investors in a research note.
Baird
Michael Ha
Buy
Maintains
$388 → $362
2025-04-15
Reason
Truist Securities
David Macdonald
Strong Buy
Maintains
$375 → $385
2025-04-11
Reason
Truist raised the firm's price target on Cigna to $385 from $375 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 results in Healthcare Services and adjusting the firm's models. The sector looks relatively well positioned in a fluid environment given the scaled, largely domestic, attractive free cash flow generating, defensive nature of the group, and while regulatory developments remain an area of focus, the Medicare Advantage final rule reinforced the firm's expectation of a better environment, the analyst tells investors in a research note.

Valuation Metrics

The current forward P/E ratio for Cigna Group (CI.N) is 9.42, compared to its 5-year average forward P/E of 10.92. For a more detailed relative valuation and DCF analysis to assess Cigna Group 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PE
10.92
Current PE
9.42
Overvalued PE
11.97
Undervalued PE
9.87

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average EV/EBITDA
9.15
Current EV/EBITDA
7.88
Overvalued EV/EBITDA
9.93
Undervalued EV/EBITDA
8.38

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Strongly Undervalued
5Y Average PS
0.42
Current PS
0.31
Overvalued PS
0.47
Undervalued PS
0.36

Financials

Annual
Quarterly
FY2025Q1
YoY :
+14.40%
65.50B
Total Revenue
FY2025Q1
YoY :
-4.62%
2.19B
Operating Profit
FY2025Q1
YoY :
-764.62%
1.41B
Net Income after Tax
FY2025Q1
YoY :
-600.00%
4.85
EPS - Diluted
FY2025Q1
YoY :
-64.91%
1.59B
Free Cash Flow
FY2025Q1
YoY :
-9.32%
9.44
Gross Profit Margin - %
FY2025Q1
YoY :
-52.33%
2.35
FCF Margin - %
FY2025Q1
YoY :
-681.08%
2.15
Net Margin - %
FY2025Q1
YoY :
+94.92%
9.98
ROIC

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
13.6M
USD
4
6-9
Months
0.0
USD
0
0-12
Months
10.5M
USD
3
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
383.4K
Volume
9
6-9
Months
558.5K
Volume
7
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
3
96.9K
Volume
Months
6-9
15
459.9K
Volume
Months
0-12
2
5.4K
Volume
Months
Congress Trading
Congress areSelling! The selling amount has increased103.13%over the last month.
Sold
0-3
Months
32.5K
USD
1
3-6
Months
16.0K
USD
2
6-9
Months
32.0K
USD
4
0-12
Months
0.0
USD
0
Bought
0-3
3
24.0K
USD
Months
3-6
2
16.0K
USD
Months
6-9
3
48.5K
USD
Months
0-12
1
8.0K
USD
Months

CI News & Events

Events Timeline

2025-07-18 (ET)
2025-07-18
06:22:51
ACA marketplace plans seek double digit rate increases for 2026, WSJ says
select
link
2025-07-18
06:17:14
U.S. Health insurers prescription drug denials on the rise, NYT says
select
link
2025-07-14 (ET)
2025-07-14
09:14:56
Fight brewing over Medicare drug negotiation program, Bloomberg Law reports
select
link
Sign Up For More Events

News

4.5
07-26Benzinga
Benzinga Bulls And Bears: T-Mobile, LendingTree, Molina Healthcare — And Trade Deal Optimism Boosts Markets
9.5
07-26Yahoo Finance
The Cigna Group (CI): Oversold on the Charts, Solid in the Fundamentals
9.5
07-24Benzinga
Centene, Cigna, Others Drop As Molina's Results Rattle Sector
Sign Up For More News

FAQ

arrow icon

What is Cigna Group (CI) stock price today?

The current price of CI is 289.92 USD — it has decreased -0.84 % in the last trading day.

arrow icon

What is Cigna Group (CI)'s business?

arrow icon

What is the price predicton of CI Stock?

arrow icon

What is Cigna Group (CI)'s revenue for the last quarter?

arrow icon

What is Cigna Group (CI)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Cigna Group (CI)'s fundamentals?

arrow icon

How many employees does Cigna Group (CI). have?

arrow icon

What is Cigna Group (CI) market cap?